Affiliation:
1. Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy
2. Department of Biomedical Sciences and Public Health, Section of Pathological Anatomy, Università Politecnica delle Marche, 60126 Ancona, Italy
Abstract
Prostate cancer is the second most common cancer in men worldwide. Prostate cancer can be treated by surgery or active surveillance when early diagnosed but, when diagnosed at an advanced or metastatic stage, radiation therapy or androgen-deprivation therapy is needed to reduce cancer progression. However, both of these therapies can cause prostate cancer resistance to treatment. Several studies demonstrated that oxidative stress is involved in cancer occurrence, development, progression and treatment resistance. The nuclear factor erythroid 2-related factor 2 (NRF2)/KEAP1 (Kelch-Like ECH-Associated Protein 1) pathway plays an important role in protecting cells against oxidative damage. Reactive oxygen species (ROS) levels and NRF2 activation can determine cell fate. In particular, toxic levels of ROS lead physiological cell death and cell tumor suppression, while lower ROS levels are associated with carcinogenesis and cancer progression. On the contrary, a high level of NRF2 promotes cell survival related to cancer progression activating an adaptive antioxidant response. In this review, we analyzed the current literature regarding the role of natural and synthetic compounds in modulating NRF2/KEAP1 signaling pathway in prostate cancer.
Reference187 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022
2. Tossetta, G., Fantone, S., Gesuita, R., Goteri, G., Senzacqua, M., Marcheggiani, F., Tiano, L., Marzioni, D., and Mazzucchelli, R. (2022). Ciliary Neurotrophic Factor Modulates Multiple Downstream Signaling Pathways in Prostate Cancer Inhibiting Cell Invasiveness. Cancers, 14.
3. Androgen deprivation therapy in the treatment of advanced prostate cancer;Perlmutter;Rev. Urol.,2007
4. AT-rich interactive domain 1A (ARID1A) cannot be considered a morphological marker for prostate cancer progression: A pilot study;Tossetta;Acta Histochem.,2022
5. Radiation Therapy in Oligometastatic Prostate Cancer;Chinniah;Int. J. Radiat. Oncol. Biol. Phys.,2022
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献